Response to “Weight-loss drugs like Wegovy could lead to an increased risk of fragility fractures in population at risk”

IF 4.7 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Obesity Pub Date : 2025-06-22 DOI:10.1002/oby.24345

Robert F. Kushner, Donna H. Ryan, Nina M. Harder-Lauridsen, Ole Kleist Jeppesen, Klaus Kallenbach, A. Michael Lincoff, Ildiko Lingvay

引用次数: 0

查看原文本刊更多论文

对“像维格威这样的减肥药可能会导致高危人群脆性骨折的风险增加”的回应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Obesity 医学-内分泌学与代谢

CiteScore

11.70

自引率

1.40%

发文量

261

审稿时长

2-4 weeks

期刊介绍： Obesity is the official journal of The Obesity Society and is the premier source of information for increasing knowledge, fostering translational research from basic to population science, and promoting better treatment for people with obesity. Obesity publishes important peer-reviewed research and cutting-edge reviews, commentaries, and public health and medical developments.